argenx SE ARGX

European equities traded in the US as American depositary receipts were trending lower late Wednesda

BOSTON, September 29, 2026--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patientsReal-world evidence from more than 1,100 U.S. MG patients indicates the value of treating earlier with VYVGART Long-term data reinforce VYVGART’s consistent safety and efficacy profile in CIDP, and Phase 4 switch data support the feasibility of a direct, one-week transition from IVIg Empasiprubart Phase 2 study results in MMN

There are good reasons behind analyst's bullish views of this biotech stock.

European equities traded in the US as American depositary receipts were tracking slightly lower Thur

argenx (ENXTBR:ARGX) drew fresh attention after its Extraordinary General Meeting confirmed Thomas M. Brakel and Khurem Farooq as new non-executive directors, prompting investors to reassess how board composition might influence longer term decision making. argenx shares trade at €835.8 after a modest pullback, with the 30-day share price return down 3.29%. The 90-day move is up 6.91%, and the year-to-date share price return is 15.47%, while the 1-year total shareholder return sits at 34.37%...

argenx has delivered a striking share-price run over the past few years, which naturally puts the microscope on what investors are paying for its earnings today. With the stock coming off a strong multi‑year performance but some recent soft patches, the key issue is whether the current market price lines up with the profits the business is generating. Over the past 5 years, argenx shares have returned 228.2%, which raises the question of how much of that move can be explained by its earnings...

Stock Market Today: The Dow Jones index falls Wednesday after the Nasdaq set a new high Tuesday. Micron and Sandisk drop.

Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.

On September 17, Halozyme (NASDAQ:HALO) priced $1.3 billion of convertible senior notes due 2033, an offering that grew from an originally planned $1.05 billion as demand came in. The notes carry a 1.50% coupon and convert into stock at $139.84 a share, a 27.5% premium to the $109.68 closing price that day. Investors who like […]

It's easy to be bullish about Argenx.

September 17, 2026 – 22:01PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced the results of the Extraordinary General Meeting of Shareholders and appointments of Thomas M. Brakel and Khurem Farooq as non-executive directors of the Company’s Board of Directors. “We welcome Tom and Khurem to the Board and look forward to learning from their combined years of leadership and expertise. Our focus at argenx today remains as

European equities traded in the US as American depositary receipts were tracking lower late Tuesday

TORONTO, September 02, 2026--BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci's agentic research environment for preclinical drug discovery, within the organization. Selected through a competitive evaluation led by argenx's own scientists, the agreement represents a significant milestone in BenchSci's expansion across European biopharma.

This biotech innovator could be in only the early chapters of its success story.

September 1, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor conferences in September: Wells Fargo 21st Annual Healthcare Conference. Fireside chat on Tuesday, September 8, 2026 at 9:30 a.m. ET in Boston, MA.Morgan Stanley 24th Annual Global Healthcare Conference. Fireside chat on Monday, September 14, 2026 at 9:15 a.m. ET in New York, NY. A li

Under its new chief, Karen Massey, Argenx is positioning its blockbuster Vyvgart to become the Keytruda of the autoimmune disease space.

Argenx stock has delivered very strong gains over the past five years, yet current valuation checks suggest investors are paying a premium rather than buying into an obvious bargain. A 209.7% return over 5 years points to a stock where expectations have risen sharply and pricing now embeds a lot of optimism. Positive Phase 3 data for Vyvgart Hytrulo in autoimmune myositis can support high growth expectations, while execution and clinical risk around expanding the immunology pipeline may...

argenx (ENXTBR:ARGX) is back in focus after reporting positive topline results from the ALKIVIA Phase 3 trial of VYVGART Hytrulo in autoimmune myositis, a rare muscle disease with limited targeted treatment options. argenx shares have reacted strongly around these developments, with a 30 day share price return of 17.54% and a 90 day share price return of 26.80%. The 1 year total shareholder return of 50.58% and 5 year total shareholder return of 209.69% suggest that momentum has been building...